Simris Alg AB (publ) (SIMRIS-B) - Total Liabilities

Latest as of June 2026: Skr136.97 Million SEK ≈ $14.74 Million USD

Based on the latest financial reports, Simris Alg AB (publ) (SIMRIS-B) has total liabilities worth Skr136.97 Million SEK (≈ $14.74 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See working capital to net assets of Simris Alg AB (publ) to evaluate short-term liquidity relative to the company's equity base.

Simris Alg AB (publ) - Total Liabilities Trend (2012–2025)

This chart illustrates how Simris Alg AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Simris Alg AB (publ).

Simris Alg AB (publ) Competitors by Total Liabilities

The table below lists competitors of Simris Alg AB (publ) ranked by their total liabilities.

Company Country Total Liabilities
SUNL.TECH.G.ADR/2DL-00005
F:S790
Germany €1.10 Billion
HYUNGJI INNOVATION & CREATIVE Co.Ltd
KQ:011080
Korea ₩25.13 Billion
Pergamon Status Dis Ticaret AS
IS:PSDTC
Turkey TL4.93 Billion
Scage Future American Depositary Shares
NASDAQ:SCAG
USA $27.43 Million
BOA Resources Ltd
AU:BOA
Australia AU$133.40K
Samjin LND Co. Ltd
KQ:054090
Korea ₩94.84 Billion
Cairn Homes PLC
LSE:CRN
UK GBX522.49 Million
J and Friends Holdings Limited
NASDAQ:JF
USA $22.85 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Simris Alg AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Simris Alg AB (publ) net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.81 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 178.57 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.99 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Simris Alg AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Simris Alg AB (publ) (2012–2025)

The table below shows the annual total liabilities of Simris Alg AB (publ) from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 Skr148.85 Million
≈ $16.02 Million
-1.69%
2024-12-31 Skr151.42 Million
≈ $16.29 Million
+1.66%
2023-12-31 Skr148.94 Million
≈ $16.03 Million
-8.45%
2022-12-31 Skr162.68 Million
≈ $17.51 Million
+1381.58%
2021-12-31 Skr10.98 Million
≈ $1.18 Million
+13.88%
2020-12-31 Skr9.64 Million
≈ $1.04 Million
-43.98%
2019-12-31 Skr17.21 Million
≈ $1.85 Million
+71.18%
2018-12-31 Skr10.05 Million
≈ $1.08 Million
-14.11%
2017-12-31 Skr11.71 Million
≈ $1.26 Million
+6.13%
2016-12-31 Skr11.03 Million
≈ $1.19 Million
-34.90%
2015-12-31 Skr16.94 Million
≈ $1.82 Million
+1461.47%
2014-12-31 Skr1.08 Million
≈ $116.76K
+54.44%
2013-12-31 Skr702.52K
≈ $75.60K
+10.93%
2012-12-31 Skr633.30K
≈ $68.15K
--

About Simris Alg AB (publ)

ST:SIMRIS-B Sweden Biotechnology
Market Cap
$17.07 Million
Skr158.60 Million SEK
Market Cap Rank
#25692 Global
#519 in Sweden
Share Price
Skr0.12
Change (1 day)
+0.43%
52-Week Range
Skr0.04 - Skr0.17
All Time High
Skr14.17
About

Simris Group AB (PUBL), a biotechnology company, develops antibody-drug conjugate (ADC) payloads in Sweden and internationally. The company develops, manufactures, and sells bioactive substances from cultured microalgae and cyanobacteria. It also offers cosmetics and skincare products; biopharmaceuticals; and dietary supplements. The company was incorporated in 2011 and is headquartered in Hammen… Read more